GeneNews to Present at AdvaMed 2012


TORONTO, Sept. 28, 2012 (GLOBE NEWSWIRE) -- GeneNews Limited (TSX:GEN), a company focused on the development and commercialization of novel blood-based tests for the early detection of diseases and personalized health management, announced today that its President and Chief Operating Officer, Gailina J. Liew, will present an update on the Company's business at the Advanced Medical Technology Association ("AdvaMed") 2012 MedTech Conference on Tuesday, October 2 at 9:45 a.m. Eastern Time. The conference will be held at the Boston Convention & Exhibition Center.

AdvaMed 2012 is a premier event for business leaders, policy-makers, investors, media and other medical technology industry stakeholders from around the world.

About GeneNews

GeneNews is a molecular diagnostics company focused on the application of blood-based RNA molecular signatures to enable early diagnosis and personalized health management. The Company has a patented core platform technology, the Sentinel Principle®, which has the power to detect and stage a range of diseases or medical conditions from a simple blood sample. GeneNews is currently applying the Sentinel Principle® in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. GeneNews' lead product, ColonSentry®, is the world's first blood test to pre-screen and assess an individual's current risk for colorectal cancer. For more information on GeneNews and ColonSentry®, go to www.GeneNews.com and www.ColonSentry.com.

Forward-Looking Statements

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.


            

Contact Data